(Q43457128)

English

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

scientific article published on 10 November 2014

In more languages
default for all languages
No label defined

No description defined

Statements

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (English)
Matthias Stelljes
Heinz-August Horst
Dorothea Wessiepe

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit